Home
News
Create
Screeners
Insights
Aspira Pathlab
59.
35
+1.15
(+1.98%)
Market Cap
₹61.08 Cr
PE Ratio
24.98
Industry
Healthcare Services
Buy
Sell
Company Performance:
1D
+1.98%
1M
+5.31%
6M
-7.41%
1Y
-5.16%
5Y
+98.49%
View Company Insights
Latest news about Aspira Pathlab
Aspira Pathlab & Diagnostics Limited Confirms Non-Applicability of Large Corporate Criteria for FY26
4 days ago
Aspira Pathlab & Diagnostics Limited has confirmed to BSE that it does not qualify as a Large Corporate under SEBI criteria for FY26, exempting it from annual disclosure requirements. The confirmation was submitted by CFO Balkrishna Talawadekar on April 15, 2026, referencing SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144. The company is therefore not required to comply with Annexure B2 disclosure requirements related to debt securities fund raising by Large Corporate entities.
Aspira Pathlab Confirms Non-Applicability of Large Corporate Status Under SEBI Regulations
4 days ago
Aspira Pathlab & Diagnostics Limited Files Compliance Certificate for Q4 FY26
5 days ago
Aspira Pathlab & Diagnostics Limited Sets March 27, 2026 as Record Date for Open Offer Under SEBI Takeover Regulations
Mar 25, 2026
Aspira Pathlab & Diagnostics Announces Resignation of Company Secretary cum Compliance Officer
Mar 07, 2026
More news about Aspira Pathlab
10
Feb 26
Aspira Pathlab Reports Q3FY26 Net Loss of ₹156.12 Lakhs Against Prior Year Profit
Aspira Pathlab & Diagnostics Limited reported a net loss of ₹156.12 lakhs for Q3FY26 against a profit of ₹37.66 lakhs in Q3FY25, with revenue declining 5.33% to ₹511.88 lakhs. For nine months FY26, the company maintained profitability at ₹74.03 lakhs despite a 45.17% decline from ₹135.02 lakhs in the previous year. The Board approved a ₹5 crore related party transaction with Yashraj Research Foundation subject to member approval.
07
Jan 26
Aspira Pathlab Submits Quarterly Compliance Certificate for Q3FY26 Under SEBI Regulations
Aspira Pathlab & Diagnostics Limited has submitted its compliance certificate under SEBI Regulation 74(5) for Q3FY26 quarter ended December 31, 2025. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper handling of securities dematerialisation processes and adherence to prescribed timelines for regulatory compliance.
02
Jan 26
Aspira Pathlab & Diagnostics Limited Announces Demise of Independent Director Dr. Alaka Keshav Deshpande
Aspira Pathlab & Diagnostics Limited announced the death of Independent Director Dr. Alaka Keshav Deshpande on December 30, 2025, at age 79. Her demise results in cessation of her directorship and memberships in the Audit Committee, Nomination & Remuneration Committee, and Stakeholder Relationship Committee. The company described her loss as irreparable and has conveyed condolences to her family while fulfilling regulatory disclosure requirements under SEBI LODR Regulations.
13
Nov 25
Aspira Pathlab Reports Q2 Loss, Appoints New Independent Director
Aspira Pathlab Diagnostics Limited reported a net loss of ₹230.49 lakhs for the quarter ended September 30, compared to a profit of ₹97.36 lakhs in the same period last year. The company appointed Mrs. Kiran Raghavendra Awasthi as an Additional Independent Director for a five-year term, effective November 12. Aspira Pathlab also acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP for ₹13.00 lakhs, effective June 30.
26
Sept 25
Aspira Pathlab & Diagnostics Receives Open Offer for 26% Stake at Rs. 55 Per Share
Five acquirers and a person acting in concert have announced an open offer to acquire 26.00% (26,76,180 equity shares) of Aspira Pathlab & Diagnostics Limited at Rs. 55.00 per share. The offer, announced on September 26, 2025, complies with SEBI regulations. Aspira, established in 1973, reported a profit of Rs. 2.07 crores in FY 2024-25, a turnaround from previous year's loss. The company has over 600 centers across India and added 91 new locations in the last fiscal year.
Aspira Pathlab
59.
35
+
1.
15
(+
1.
98
%)
1 Year Returns:
-5.16%
Industry Peers
Dr. Lal Path Labs
1,402.10
(-
0.
62
%)
Vijaya Diagnostic Centre
1,022.55
(+
0.
33
%)
Metropolis Healthcare
471.70
(-
0.
12
%)
Thyrocare Technologies
389.05
(-
1.
34
%)
Nephrocare Health Services
585.80
(+
3.
27
%)
Krsnaa Diagnostics
622.75
(+
1.
01
%)
Suraksha Diagnostic
282.57
(+
0.
24
%)
One Global Service Provider
645.95
(-
1.
96
%)
3B BlackBio DX
1,315.00
(+
5.
51
%)
Sastasundar Ventures
269.15
(-
0.
26
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO